Trending Topic

3d medical x ray of knee pain with arthritis inflammation and tendon injury, copy space
9 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival time has improved from just 6 months to approximately 6 years with the use of […]

Mya C Schiess, MDS 2020 – Stem Cell Therapy for Parkinson’s Disease (Part 2)

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Published Online: Oct 21st 2020

Mya C Schiess (McGovern Medical School at UTHealth, Houston, TX, USA) discusses promising findings from a phase I study (ClinicalTrials.gov identifier: NCT02611167), which was the focus of her presentation entitled: Allogeneic bone marrow-derived mesenchymal stem cells safety and tolerability in idiopathic Parkinson’s disease.

Questions
1. Could you tell us about the design of your phase I study and its findings? (0:06)
2. Which patients are likely to benefit most from this approach and in whom is it contraindicated? (5:57)
3. What were the limitations of this study and what other studies are planned? (7:47)

See also the 1st part of this interview here.

Disclosures: Prof. Mya Schiess is the principal investigator of the study discussed in this video interview, which was sponsored by philanthropic support to the Regenerative Movement Disorders Fund and conducted at The University of Texas Health Science Center, Houston, TX, USA.

Support: Interview and filming supported by Touch Medical Media.

Filmed as a highlight of the International Parkinson and Movement Disorder Society MDS Virtual Congress 2020.

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Close Popup